Mauna Kea Technologies Shares Eligible for New PEA-PME Savings Plan

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, FR0010609263), leader in the optical biopsy market, today confirmed that its shares are eligible for the new "PEA-PME” SME equity savings plan.

Mauna Kea Technologies meets the eligibility criteria for "PEA-PME” SME equity savings plans in compliance with Decree n° 2014-283 issued on March 4, 2014 relating to the application of article 70 of the 2014 finance law n° 2013-1278:

• a workforce of less than 5,000 staff;
• annual revenue of less than €1,500m or a balance sheet of less than €2,000m.

Investors can include Mauna Kea Technologies shares in PEA-PME savings accounts, a new plan aimed at encouraging investments in small and mid-cap companies:

• identical terms and conditions for opening a new account as the existing equity savings plan (PEA) accounts;
• ceiling set at €75,000;
• individuals can hold PEA-PME savings account in a different financial institution than where they hold an existing PEA account;
• same tax incentives as PEA equity savings plan.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use during digestive and pulmonary endoscopy procedures, including pancreatic and biliary endoscopic explorations as well as fine needle aspiration procedures. Mauna Kea Technologies also obtained CE mark for a complete range of probes dedicated to urology.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com